Quipt Home Medical > Press Releases > Quipt Home Medical to Begin Trading on Nasdaq

Quipt Home Medical to Begin Trading on Nasdaq

CINCINNATI, May 27, 2021 Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSXV: QIPT), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is pleased to announce the start of trading on The Nasdaq Capital Market (“Nasdaq”), under the trading ticker symbol “QIPT” at the market open today. The Company’s common shares will continue to be listed on the TSX Venture Exchange under the symbol “QIPT”.

Quipt utilizes a technology-driven, patient centric model to meet the one-of-a-kind needs of every patient in its ecosystem. Supported by the reach and the reputation of local brands, the Company strives to enrich the lives of its patients by providing full-service home respiratory solutions to suit every kind of need, for every kind of patient. Quipt operates out of 51 locations in 11 states with over 17,000 referring physicians and approximately 120,000 current active patients.

“Today marks the culmination of the hard work and dedication of the Quipt entire team. We are extremely excited to join Nasdaq at such an important time within our company’s history,” commented Greg Crawford, CEO and Chairman of Quipt. “Given our strong growth, we believe this listing will further enhance our visibility globally, allowing us to garner awareness with a larger audience of institutional investors and ultimately unlock shareholder value and increase liquidity in the future.”

As a reminder, Quipt will host its Q2 Fiscal 2021 earnings conference call and audio webcast on Tuesday, June 1, 2021 at 10:00 a.m. (EST).

Conference Call Details:Canada/US Toll Free:1 (800) 319 4610International:1 (604) 638 5340

Audio Webcast Details:

The live audio webcast can be found on the investor section of the Company’s website through the following link: www.quipthomemedical.com


ABOUT QUIPT HOME MEDICAL CORP.

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services and making life easier for the patient.

Forward-Looking Statements

Certain statements contained in this press release constitute “forward-looking information” as such term is ‎‎‎‎defined in applicable Canadian and United States securities legislation. The words “may”, “would”, “could”, “should”, “potential”, ‎‎‎‎‎”will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate ‎‎‎‎to the Company, including the anticipated results of a listing on Nasdaq, are intended to identify ‎forward-looking information. All ‎statements other than ‎statements of ‎historical fact may be forward-looking ‎information. Such statements reflect the ‎Company’s current ‎views and ‎intentions with respect to future events, and ‎current information available to the ‎Company, and are ‎subject to ‎certain risks, uncertainties and assumptions. Many factors ‎‎could ‎cause the actual results, performance or achievements that may be expressed or ‎implied by such forward-‎‎looking ‎information to vary from those described herein should one or more of these risks ‎or uncertainties ‎‎materialize. ‎Examples of such risk factors include, without limitation: credit; market (including ‎equity, commodity, ‎‎foreign ‎exchange and interest rate); liquidity; operational (including technology and ‎infrastructure); ‎‎reputational; ‎insurance; strategic; regulatory; legal; environmental; capital adequacy; the ‎general business and ‎‎economic ‎conditions in the regions in which the Company operates; the ability of the ‎Company to execute on key ‎‎priorities, ‎including the successful completion of acquisitions, business retention, and ‎strategic plans and to ‎‎attract, develop ‎and retain key executives; difficulty integrating newly acquired businesses; ‎the ability to ‎‎implement business ‎strategies and pursue business opportunities; low profit market segments; ‎disruptions in or ‎‎attacks (including ‎cyber-attacks) on the Company’s information technology, internet, network ‎access or other ‎‎voice or data ‎communications systems or services; the evolution of various types of fraud or other ‎criminal ‎‎behavior to which ‎the Company is exposed; the failure of third parties to comply with their obligations to ‎the ‎‎Company or its ‎affiliates; the impact of new and changes to, or application of, current laws and regulations; ‎‎‎decline of ‎reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; ‎‎‎‎dependence on key suppliers; granting of permits and licenses in a highly regulated business; the overall difficult ‎‎‎‎litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased ‎‎‎‎funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds ‎‎‎‎and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, ‎‎‎‎and methods used by the Company; the occurrence of natural and unnatural catastrophic events ‎and claims ‎‎‎‎resulting from such events; and risks related to COVID-19 including various recommendations, orders ‎and ‎‎‎measures of governmental ‎authorities ‎to try to limit the pandemic, including travel restrictions, border closures, ‎‎‎‎non-essential business ‎closures, ‎quarantines, self-isolations, shelters-in-place and social distancing, disruptions ‎‎‎to ‎markets, economic ‎activity, ‎financing, supply chains and sales channels, and a deterioration of general ‎‎‎economic ‎conditions ‎including a ‎possible national or global recession‎; as well as those risk factors discussed or ‎‎‎referred to in ‎the Company’s disclosure ‎documents filed with United States Securities and Exchange Commission and available at www.sec.gov, and with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. Should any factor affect the Company in an unexpected ‎‎‎manner, or should ‎assumptions ‎underlying the forward-looking information prove incorrect, the actual results or ‎‎‎events may differ ‎materially ‎from the results or events predicted. Any such forward-looking information is ‎‎‎expressly qualified in its ‎entirety by ‎this cautionary statement. Moreover, the Company does not assume ‎‎‎responsibility for the accuracy or ‎‎completeness of such forward-looking information. The forward-looking ‎‎‎information included in this press release ‎is ‎made as of the date of this press release and the Company undertakes ‎‎‎no obligation to publicly update or revise ‎any ‎forward-looking information, other than as required by applicable ‎‎‎law.‎

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in ‎the policies of ‎the ‎TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of ‎this release.‎

For further information please visit our website at www.quipthomemedical.com, or contact:‎

Cole Stevens
VP of Corporate Development
Quipt Home Medical Corp.
859-300-6455
[email protected]

Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.
859-300-6455
[email protected]